1. Novel genetic and epigenetic biomarkers have been identified that are associated with prognosis or therapeutic responses in stage II/III colorectal cancer (CRC).
2. Recent progress in next-generation sequencing and high-throughput technologies has greatly promoted biomarker discovery as well as understanding of the underlying mechanisms in CRC.
3. This review discusses strategies of biomarker discovery and summarizes the status and assesses the utility of previously published biomarkers in CRC.
The article is generally reliable, providing a comprehensive overview of novel genetic and epigenetic biomarkers for prognostic and predictive significance in stage II/III colorectal cancer (CRC). The authors provide an extensive discussion on strategies for biomarker discovery, summarizing the status and assessing the utility of previously published biomarkers in CRC. The article is well-structured, clearly outlining its objectives, methodology, results, and conclusions.
The article does not appear to be biased or one-sided; it presents both sides equally by discussing both potential benefits and risks associated with using these novel genetic and epigenetic biomarkers for prognostic and predictive purposes. Furthermore, it provides evidence to support its claims by citing relevant studies from other researchers.
The only potential issue with this article is that it does not explore any counterarguments or alternative perspectives on the use of these novel genetic and epigenetic biomarkers for prognostic and predictive purposes. However, this is understandable given that this is a review article rather than a research paper exploring different perspectives on this topic.